28 May 2020  
EMA/CHMP/254416/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Ofev 
nintedanib 
On 28 May 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Ofev.  
The marketing authorisation holder for this medicinal product is Boehringer Ingelheim International 
GmbH. 
The CHMP adopted a new indication as follows: 
“Ofev is indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases with a 
progressive phenotype.” 
For information, the full indications for OFEV will be as follows: 
Ofev is indicated in adults for the treatment of idiopathic pulmonary fibrosis. 
Ofev is indicated in adults for the treatment of systemic sclerosis associated interstitial lung disease. 
Ofev is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases with a 
progressive phenotype. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
 
 
 
 
